7 lectures · 244 items
45 min
4 min
2 min
7 min
5 min
11 min
5 min
New AI decision-support tool for heart failure enters clinical validation: the STRATIFYHF study
Heart failure is common in people with atrial fibrillation detected during screening
Enhanced remote medication program boosts GDMT prescriptions for high CV or kidney risk in T2D patients
STRATIFY-HF A European collaboration to develop an AI based support system for risk stratification and early detection of heart failureEducation, exchange, guidance and interaction during EPCCS Summit 2019Complexities of managing heart failure
Slides | Complexities of managing heart failure
Praktičan vodič za dijagnostikovanje i lečenje srčane insuficijencije u primarnoj zdravstvenoj zaštiti (PZZ)Complexities of managing heart failure in primary care
Slides | Managing complex heart failure: a specialist view of the primary/ secondary interface
Slides | Managing heart failure in primary care: The GP perspective
Практична настанова по діагностиці та менеджменту серцевої недостатності в системі первинної медичної допомоги
Chronické srdcové zlyhávanie
EPCCS Practical Guidance on Heart Failure Diagnosis and Management in Primary CareEPCCS Heart Failure Guidance published as Clinical Intelligence in Br J Gen Prac
What’s the new evidence base for heart failure diagnosis & management?This review outlines a practical framework for integrating GLP-1 receptor agonists, SGLT2 inhibitors, and mineralocorticoid receptor antagonists into maintenance immunosuppression for kidney…
In a multicentre cohort of 1,014 patients with persistent left ventricular dysfunction following myocardial infarction and an implanted cardioverter-defibrillator (ICD), ventricular arrhythmias (VA)…
the glucagon/GLP-1 dual agonist survodutide does not raise cardiovascular risk in obesity (5-point MACE HR 0.89), delivers 13.7 percent weight loss and 6.7 mmHg lower blood pressure, but one in five stops for gastrointestinal effects
Presented in LBS.05 at AHA 2026 (Monday 9 November) by principal investigator Biykem Bozkurt and published simultaneously in The Lancet; the figures below come from the Boehringer Ingelheim release…
patients who received vutrisiran from the start of HELIOS-B have 37 percent fewer deaths or cardiovascular events through month 48 than those who began after the placebo phase, and eplontersen measurably shrinks myocardial amyloid on MRI in CARDIO-TTRansform
Two Circulation papers behind FS.11 at AHA 2026 (Monday 9 November); figures from the published abstracts. HELIOS-B open-label extension (Garcia-Pavia et al., online 3 November; Peter van der Meer of…
in moderate aortic stenosis with at-risk features, upfront TAVR gives fewer deaths or heart-failure events at two years than clinical surveillance (16.7 versus 23.9 percent), but the gain lies entirely in heart failure and not in mortality
Presented again in FS.13 at AHA 2026 (Monday 9 November) after its TCT 2026 debut and NEJM publication of 2 November. PROGRESS randomised 744 patients (mean age 78, 39.1 percent women, 45.6 percent…
dapagliflozin slows the loss of kidney function in heart transplant recipients, with Rotterdam, Groningen and Utrecht as three of the six centres
Presented in FS.07 at AHA 2026 (Sunday 8 November) and published simultaneously in Circulation. DAPARHT (Dapagliflozin for Renal Protection in Heart Transplant Recipients) is an…
a single ferric derisomaltose infusion improves peak VO2, walking distance and NYHA class at twelve weeks in HFpEF with iron deficiency, but not patient-reported health status
Presented in FS.07 at AHA 2026 (Sunday 8 November, Gregory D. Lewis, Mass General Brigham, Boston) and published simultaneously in Circulation. IRONMET-HFpEF is a single-centre, double-blind…
in atrioventricular block, left bundle branch pacing cuts death, heart failure hospitalisation or pacing-induced cardiomyopathy by 59 percent compared with conventional right ventricular pacing; the trial was stopped early
Presented in LBS.04 at AHA 2026 (Sunday 8 November) and published simultaneously in NEJM. OptimPacing is an investigator-initiated, open-label randomised trial at 17 centres in mainland China, Hong…
This review evaluates the impact of fixed-dose combination therapies (polypills) on adherence and cardiovascular outcomes across primary and secondary prevention, as well as in heart failure…
A Systematic Review and Meta-Analysis.
A systematic review and meta-analysis of 31 studies (26,948 patients) compared fixed and age-dependent NT-proBNP thresholds for diagnosing acute heart failure in dyspneic emergency department…
SURPASS-CVOT analysis.
In a post-hoc analysis of the SURPASS-CVOT trial, patients with type 2 diabetes and established atherosclerotic cardiovascular disease received either tirzepatide or dulaglutide over a mean follow-up…
A large real-world propensity-matched cohort study (N=271,685 per arm) compared cardiovascular outcomes in patients with type 2 diabetes treated with tirzepatide versus semaglutide. Tirzepatide was…